GenFleet Therapeutics (GenFleet; SEHK: 02595) has initiated a multicenter, open-label, randomized Phase II study to evaluate its oral KRAS G12D inhibitor GFH375 as a first-line treatment for advanced KRAS G12D-mutant non-small cell lung cancer (NSCLC).
The trial will enroll treatment-naïve patients and allocate them to one of three arms: GFH375 monotherapy, GFH375 plus the EGFR antibody cetuximab, or GFH375 combined with pemetrexed-based chemotherapy. Guangdong Provincial People’s Hospital will serve as the lead site, with additional centers across China participating.
Regulatory momentum for GFH375 remains strong. The molecule is the first KRAS G12D inhibitor to secure Breakthrough Therapy Designation from China’s National Medical Products Administration for NSCLC and also holds U.S. FDA Fast Track designation for locally advanced unresectable or metastatic KRAS G12D-mutant NSCLC. In parallel, GFH375 is already being investigated in the world’s first registrational Phase III monotherapy study for this patient population.
GenFleet highlighted prior data indicating “best-in-class” efficacy of GFH375 monotherapy in NSCLC, with updated Phase I/II results (Abstract 2333) slated for oral presentation at the World Conference on Lung Cancer on 14 September in Seoul. Preclinical findings presented at the 2026 AACR Annual Meeting showed that GFH375 combined with cetuximab produced markedly superior antitumor activity versus either agent alone in KRAS G12D-mutant NSCLC models. Early readouts from an ongoing Phase Ib/II study of GFH375 plus chemotherapy or cetuximab across solid tumors have so far indicated a favorable safety and tolerability profile, with no significant overlapping toxicities. Combination data have been invited for a Late-Breaking Abstract submission at the 2026 ESMO Annual Meeting.
GFH375 (also designated VS-7375) is a potent, highly selective, non-covalent inhibitor of KRAS G12D in both GDP- and GTP-bound conformations. Preclinical assays demonstrated dose- and duration-dependent pathway inhibition with low off-target kinase activity. Under a collaboration with U.S.-based Verastem Oncology, the partner exercised its option in January 2025 to license GFH375 for development and commercialization outside China; GenFleet retains China rights.
Current standard-of-care regimens for KRAS G12D-mutant NSCLC follow protocols for oncogene-negative disease and have produced only modest survival gains, with multiple real-world studies indicating inferior outcomes versus other KRAS genotypes. GenFleet’s expanded clinical program aims to address this therapeutic gap by moving GFH375-based regimens into earlier treatment lines.
Shareholders and potential investors are reminded that clinical development outcomes remain subject to significant R&D and regulatory uncertainties, and the company cannot guarantee ultimate approval or commercialization of GFH375.